XT
RLMD icon

XTX Topco’s Relmada Therapeutics RLMD Stock Holding History

XTX Topco’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33,606
Closed -$234K – 4628
2026
Q1 		$234K Sell
33,606
-7,687
-19% -$36.4K ﹤0.01% 2724
2025
Q4 		$199K Buy
+41,293
New +$138K 0.01% 2404
2025
Q3 		– Sell
-46,039
Closed -$27.6K – 3157
2025
Q2 		$27.6K Buy
+46,039
New +$23.6K ﹤0.01% 2121
2024
Q1 		– Sell
-22,009
Closed -$91.1K – 2242
2023
Q4 		$91.1K Buy
+22,009
New +$65.2K 0.02% 1137
2023
Q3 		– Sell
-10,767
Closed -$26.5K – 1941
2023
Q2 		$26.5K Sell
10,767
-75,500
-88% -$209K ﹤0.01% 1299
2023
Q1 		$195K Sell
86,267
-43,120
-33% -$149K 0.04% 969
2022
Q4 		$452K Buy
+129,387
New +$1.14M 0.1% 350

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

XTX Topco's RLMD Position: Q2 2026 in Review

XTX Topco sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 33,606 shares — an estimated $234K sold.

XTX Topco first reported a position in RLMD in Q4 2022 and held it in 7 quarters. The position peaked at $452K in Q4 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • XTX Topco reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 33,606 Relmada Therapeutics shares in Q2 2026, an estimated $234K.
  • XTX Topco first reported a position in Relmada Therapeutics in Q4 2022 and held it in 7 quarters.
  • XTX Topco's Relmada Therapeutics position peaked at $452K in Q4 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.